Omkar Speciality Chemicals Ltd
Incorporated in 1993, Omkar Specialty Chemicals Ltd is engaged in the manufacture and sale of Specialty Chemicals and Pharma Intermediates for Chemical and Allied Industries.
- Market Cap ₹ 19.8 Cr.
- Current Price ₹ 9.63
- High / Low ₹ 11.6 / 5.65
- Stock P/E
- Book Value ₹ -83.0
- Dividend Yield 0.00 %
- ROCE -10.5 %
- ROE %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 58.0 to 32.6 days.
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -40.8% over past five years.
- Contingent liabilities of Rs.13.1 Cr.
- Working capital days have increased from 137 days to 285 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
107 | 167 | 202 | 210 | 193 | 319 | 317 | 198 | 43 | 57 | 45 | 23 | 19 | |
85 | 134 | 165 | 177 | 164 | 274 | 259 | 241 | 44 | 57 | 38 | 29 | 26 | |
Operating Profit | 21 | 33 | 36 | 33 | 29 | 45 | 57 | -43 | -1 | -0 | 7 | -6 | -6 |
OPM % | 20% | 20% | 18% | 16% | 15% | 14% | 18% | -22% | -3% | -0% | 16% | -25% | -32% |
1 | 4 | 6 | 6 | 5 | 9 | -161 | -49 | 12 | 0 | 5 | 1 | 1 | |
Interest | 5 | 8 | 7 | 12 | 11 | 17 | 22 | 26 | 15 | 5 | 6 | 6 | 6 |
Depreciation | 2 | 6 | 6 | 6 | 2 | 4 | 11 | 8 | 8 | 7 | 4 | 2 | 2 |
Profit before tax | 15 | 23 | 29 | 21 | 20 | 33 | -137 | -127 | -12 | -11 | 3 | -13 | -13 |
Tax % | 31% | 29% | 28% | 30% | 12% | 33% | -20% | -18% | 46% | 29% | 36% | 0% | |
10 | 16 | 21 | 15 | 18 | 22 | -109 | -104 | -17 | -15 | 2 | -13 | -13 | |
EPS in Rs | 5.17 | 8.39 | 10.61 | 7.45 | 8.70 | 10.78 | -53.09 | -50.47 | -8.19 | -7.10 | 0.98 | -6.12 | -6.42 |
Dividend Payout % | 19% | 15% | 14% | 20% | 17% | 14% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | -18% |
5 Years: | -41% |
3 Years: | -19% |
TTM: | -59% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 16% |
TTM: | -345% |
Stock Price CAGR | |
---|---|
10 Years: | -18% |
5 Years: | 19% |
3 Years: | -37% |
1 Year: | 1% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 20 | 20 | 20 | 20 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
Reserves | 73 | 86 | 104 | 115 | 142 | 161 | -23 | -146 | -169 | -183 | -179 | -192 |
45 | 78 | 118 | 154 | 176 | 186 | 181 | 233 | 230 | 233 | 228 | 226 | |
35 | 33 | 41 | 53 | 50 | 80 | 129 | 28 | 26 | 26 | 17 | 18 | |
Total Liabilities | 172 | 217 | 283 | 342 | 389 | 447 | 307 | 136 | 107 | 97 | 86 | 72 |
21 | 36 | 44 | 43 | 68 | 78 | 83 | 76 | 68 | 53 | 28 | 26 | |
CWIP | 18 | 31 | 40 | 69 | 107 | 113 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 1 | 2 | 11 | 14 | 14 | 14 | 0 | 11 | 0 | 0 | 1 | 0 |
133 | 148 | 187 | 217 | 199 | 242 | 224 | 49 | 38 | 44 | 58 | 46 | |
Total Assets | 172 | 217 | 283 | 342 | 389 | 447 | 307 | 136 | 107 | 97 | 86 | 72 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
4 | -0 | 0 | 24 | 53 | -9 | 107 | 26 | 1 | 4 | -16 | 1 | |
-45 | -32 | -46 | -43 | -76 | 12 | -120 | -64 | 11 | 2 | 17 | 0 | |
82 | 22 | 36 | 15 | 17 | -8 | 16 | 35 | -14 | -5 | -1 | -1 | |
Net Cash Flow | 41 | -10 | -10 | -3 | -6 | -6 | 3 | -3 | -1 | 0 | -0 | 0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 93 | 84 | 111 | 148 | 129 | 117 | 90 | 19 | 74 | 30 | 111 | 33 |
Inventory Days | 147 | 168 | 170 | 156 | 149 | 99 | 110 | 8 | 37 | 31 | 18 | 40 |
Days Payable | 106 | 81 | 73 | 94 | 96 | 81 | 184 | 32 | 259 | 148 | 139 | 215 |
Cash Conversion Cycle | 135 | 172 | 209 | 210 | 181 | 135 | 16 | -5 | -147 | -86 | -10 | -143 |
Working Capital Days | 180 | 156 | 183 | 184 | 139 | 148 | 48 | -26 | -119 | -38 | 165 | 285 |
ROCE % | 22% | 19% | 17% | 12% | 10% | 14% | 18% | -34% | -8% | -8% | 7% | -11% |
Documents
Announcements
-
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors
20 Aug 2023 - Notice for sixth meeting of creditors for Omkar Speciality Chemicals.
-
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors
19 Jul 2023 - Notice for fifth meeting of creditors for Omkar Speciality Chemicals.
- Corporate Insolvency Resolution Process (CIRP)-Appointment of Interim Resolution Professional (IRP) 29 Dec 2022
-
Clarification sought from Omkar Speciality Chemicals Ltd
25 Oct 2022 - Exchange has sought clarification from Omkar Speciality Chemicals Ltd on October 25, 2022, with reference to Movement in Price.
-
Clarification sought from Omkar Speciality Chemicals Ltd
25 Oct 2022 - Exchange has sought clarification from Omkar Speciality Chemicals Ltd on October 24, 2022, with reference to Movement in Volume.
Annual reports
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Aug 2017TranscriptPPT
-
May 2017TranscriptPPT
-
May 2017TranscriptPPT
-
Nov 2016TranscriptPPT
-
Nov 2016TranscriptPPT
-
Aug 2016TranscriptPPT
-
Aug 2016TranscriptPPT
-
Jun 2016Transcript PPT
-
Apr 2016TranscriptPPT
-
Feb 2016TranscriptPPT
-
Dec 2015TranscriptNotesPPT
Product Portfolio:[1]
Company manufactures range of Organic, Inorganic and Intermediates, comprising 90+ products. These includes inorganic intermediates like derivatives of Molybdenum, Selenium, Iodine, Cobalt, and Bismuth; organic intermediates like Tartaric acid derivatives and various other organic inorganic intermediates like Iodobenzene Diacetate, Dess Martin Periodinane, Vanadyl Sulphate etc.
a) Iodine Derivatives[2]
b) Advance Intermediates[3]
c) Selenium Derivatives[4]
d) Resolving Agent[5]